← Pacific Biosciences of California overview

Pacific Biosciences of California vs Personalis: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Pacific Biosciences of California (PACB)

Q3 2026
▲3▼1

PacBio cuts outlook, delays breakeven, but new products and partnerships lift shares

  • PacBio slashes 2026 revenue guidance and pushes cash-flow breakeven to 2028 PacBio cut its 2026 revenue forecast to $155–$165 million and now expects cash-flow breakeven in 2028, a year later than planned. The SPRQ-Nx chemistry transition is slower than expected, and instrument demand is weak. This makes the company's path to profitability longer and riskier, pressuring the stock.

    This is the main negative force this period, directly lowering revenue expectations and delaying profitability.

  • New SPRQ-Nx chemistry boosts output and cuts costs for Vega system PacBio announced SPRQ-Nx chemistry and a software update for its Vega sequencer, increasing data output by 50% and cutting cost per gigabase by about 40%. It also adds multiomic capabilities and compliance features. This should make PacBio's products more competitive and attractive to customers, supporting future sales.

    This is a new product improvement that could drive future demand and offset some of the negative guidance.

  • EpiSign-Geneyx partnership incorporates PacBio HiFi sequencing for rare disease analysis EpiSign and Geneyx announced a partnership to integrate genomic and epigenomic analysis for rare diseases, using PacBio HiFi sequencing data. This expands the use of PacBio's platform in clinical research and could lead to more sales. The stock jumped 9.9% on the news, hitting a new 52-week high.

    This is a new partnership that directly involves PacBio's technology and drove a significant stock move.

  • Sampled wins VA contract using PacBio Revio systems Genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems. This validates PacBio's technology in a large government research setting and could lead to more orders. The stock rose 5.8% on the day.

    This is a new contract that directly benefits PacBio by increasing demand for its Revio systems.

September 2026
▲3▼1

PacBio cuts outlook, delays breakeven, but new products and partnerships lift shares

  • PacBio slashes 2026 revenue guidance and pushes cash-flow breakeven to 2028 PacBio cut its 2026 revenue forecast to $155–$165 million and now expects cash-flow breakeven in 2028, a year later than planned. The SPRQ-Nx chemistry transition is slower than expected, and instrument demand is weak. This makes the company's path to profitability longer and riskier, pressuring the stock.

    This is the main negative force this period, directly lowering revenue expectations and delaying profitability.

  • New SPRQ-Nx chemistry boosts output and cuts costs for Vega system PacBio announced SPRQ-Nx chemistry and a software update for its Vega sequencer, increasing data output by 50% and cutting cost per gigabase by about 40%. It also adds multiomic capabilities and compliance features. This should make PacBio's products more competitive and attractive to customers, supporting future sales.

    This is a new product improvement that could drive future demand and offset some of the negative guidance.

  • EpiSign-Geneyx partnership incorporates PacBio HiFi sequencing for rare disease analysis EpiSign and Geneyx announced a partnership to integrate genomic and epigenomic analysis for rare diseases, using PacBio HiFi sequencing data. This expands the use of PacBio's platform in clinical research and could lead to more sales. The stock jumped 9.9% on the news, hitting a new 52-week high.

    This is a new partnership that directly involves PacBio's technology and drove a significant stock move.

  • Sampled wins VA contract using PacBio Revio systems Genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems. This validates PacBio's technology in a large government research setting and could lead to more orders. The stock rose 5.8% on the day.

    This is a new contract that directly benefits PacBio by increasing demand for its Revio systems.

Latest
▲3▼1

PacBio cuts outlook, delays breakeven, but new products and partnerships lift shares

  • PacBio slashes 2026 revenue guidance and pushes cash-flow breakeven to 2028 PacBio cut its 2026 revenue forecast to $155–$165 million and now expects cash-flow breakeven in 2028, a year later than planned. The SPRQ-Nx chemistry transition is slower than expected, and instrument demand is weak. This makes the company's path to profitability longer and riskier, pressuring the stock.

    This is the main negative force this period, directly lowering revenue expectations and delaying profitability.

  • New SPRQ-Nx chemistry boosts output and cuts costs for Vega system PacBio announced SPRQ-Nx chemistry and a software update for its Vega sequencer, increasing data output by 50% and cutting cost per gigabase by about 40%. It also adds multiomic capabilities and compliance features. This should make PacBio's products more competitive and attractive to customers, supporting future sales.

    This is a new product improvement that could drive future demand and offset some of the negative guidance.

  • EpiSign-Geneyx partnership incorporates PacBio HiFi sequencing for rare disease analysis EpiSign and Geneyx announced a partnership to integrate genomic and epigenomic analysis for rare diseases, using PacBio HiFi sequencing data. This expands the use of PacBio's platform in clinical research and could lead to more sales. The stock jumped 9.9% on the news, hitting a new 52-week high.

    This is a new partnership that directly involves PacBio's technology and drove a significant stock move.

  • Sampled wins VA contract using PacBio Revio systems Genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems. This validates PacBio's technology in a large government research setting and could lead to more orders. The stock rose 5.8% on the day.

    This is a new contract that directly benefits PacBio by increasing demand for its Revio systems.

Personalis Inc (PSNL)

Q3 2026
▲2▼2

Personalis stuck near $16.25 Tempus buyout as higher bid hopes fade

  • Tempus to buy Personalis at $16.25 a share Tempus AI agreed to buy Personalis for $16.25 a share, about $1.5 billion, a premium to where the stock traded before the news. That buyout price now acts like a ceiling and a floor for the shares, anchoring PSNL near the deal value.

    The takeover itself is the single biggest force setting PSNL's price.

  • Law firms question whether the sale price is fair Several investor-rights law firms opened investigations into whether Personalis's board ran a fair sale process, given Tempus's existing stake and partnership. This adds uncertainty and keeps alive the small chance of a bump in price or extra disclosures, but no higher offer has appeared.

    Legal challenges are a real counterweight that could change deal terms or timing.

  • Tempus's health strengthens the buyer's stock Tempus returned to profit, raised its 2026 revenue outlook, and its mRNA melanoma trial succeeded, sending its shares sharply higher. Because part of the Personalis price is paid in Tempus stock, a stronger Tempus makes the deal look more secure and valuable to PSNL holders.

    The buyer's improving finances and trial win directly support the value of the stock-and-cash consideration.

  • Analysts see no competing bid, downgrade PSNL Craig-Hallum and BTIG downgraded Personalis, saying a higher bid is unlikely because Tempus is the key seller of Personalis's MRD test and Merck, a big shareholder, backs the deal. The stock fell on that view, as investors accept the $16.25 price is probably final.

    This explains why PSNL trades near the deal price instead of rallying on takeover hopes.

August 2026
▲2▼2

Personalis stuck near $16.25 Tempus buyout as higher bid hopes fade

  • Tempus to buy Personalis at $16.25 a share Tempus AI agreed to buy Personalis for $16.25 a share, about $1.5 billion, a premium to where the stock traded before the news. That buyout price now acts like a ceiling and a floor for the shares, anchoring PSNL near the deal value.

    The takeover itself is the single biggest force setting PSNL's price.

  • Law firms question whether the sale price is fair Several investor-rights law firms opened investigations into whether Personalis's board ran a fair sale process, given Tempus's existing stake and partnership. This adds uncertainty and keeps alive the small chance of a bump in price or extra disclosures, but no higher offer has appeared.

    Legal challenges are a real counterweight that could change deal terms or timing.

  • Tempus's health strengthens the buyer's stock Tempus returned to profit, raised its 2026 revenue outlook, and its mRNA melanoma trial succeeded, sending its shares sharply higher. Because part of the Personalis price is paid in Tempus stock, a stronger Tempus makes the deal look more secure and valuable to PSNL holders.

    The buyer's improving finances and trial win directly support the value of the stock-and-cash consideration.

  • Analysts see no competing bid, downgrade PSNL Craig-Hallum and BTIG downgraded Personalis, saying a higher bid is unlikely because Tempus is the key seller of Personalis's MRD test and Merck, a big shareholder, backs the deal. The stock fell on that view, as investors accept the $16.25 price is probably final.

    This explains why PSNL trades near the deal price instead of rallying on takeover hopes.

Latest
▲2▼2

Personalis stuck near $16.25 Tempus buyout as higher bid hopes fade

  • Tempus to buy Personalis at $16.25 a share Tempus AI agreed to buy Personalis for $16.25 a share, about $1.5 billion, a premium to where the stock traded before the news. That buyout price now acts like a ceiling and a floor for the shares, anchoring PSNL near the deal value.

    The takeover itself is the single biggest force setting PSNL's price.

  • Law firms question whether the sale price is fair Several investor-rights law firms opened investigations into whether Personalis's board ran a fair sale process, given Tempus's existing stake and partnership. This adds uncertainty and keeps alive the small chance of a bump in price or extra disclosures, but no higher offer has appeared.

    Legal challenges are a real counterweight that could change deal terms or timing.

  • Tempus's health strengthens the buyer's stock Tempus returned to profit, raised its 2026 revenue outlook, and its mRNA melanoma trial succeeded, sending its shares sharply higher. Because part of the Personalis price is paid in Tempus stock, a stronger Tempus makes the deal look more secure and valuable to PSNL holders.

    The buyer's improving finances and trial win directly support the value of the stock-and-cash consideration.

  • Analysts see no competing bid, downgrade PSNL Craig-Hallum and BTIG downgraded Personalis, saying a higher bid is unlikely because Tempus is the key seller of Personalis's MRD test and Merck, a big shareholder, backs the deal. The stock fell on that view, as investors accept the $16.25 price is probably final.

    This explains why PSNL trades near the deal price instead of rallying on takeover hopes.